Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and US-based Intuitive Surgical Inc., has announced the official launch of the Da Vinci Xi surgical robot at the 6th China International Import Expo (CIIE) in Shanghai. The Da Vinci Xi is a state-of-the-art thoracoabdominal endoscopic surgery control system that marks a significant advancement in the field of robotic surgery.
History of the Joint Venture and Product Introduction
In 2011, Fosun Pharma merged its medical device business with US firm Chindex International Inc. to establish Chindex Medical Holdings (BVI) Ltd, a joint venture that obtained exclusive agency rights to the Da Vinci surgical robot in mainland China. Building on this foundation, Fosun granted Intuitive Surgical-Fosun the exclusive distribution rights to the technology in mainland China, Hong Kong, and Macau in January 2019. This strategic move was further solidified by the establishment of Intuitive Surgical’s medical robot manufacturing R&D center in Pudong in August last year. The locally manufactured fourth-generation Da Vinci Xi surgical robot received marketing approval in China this year, signifying a major milestone for the joint venture.
Significance of the Launch
The launch of the Da Vinci Xi surgical robot at CIIE highlights the commitment of Intuitive Surgical-Fosun Medical to bringing cutting-edge medical technology to the Chinese market. The system’s introduction is expected to enhance surgical capabilities and patient outcomes in the region, offering a prime example of the integration of medical innovation and international collaboration.-Fineline Info & Tech
